SecurityWSPOF / WSP Global Inc (92938W202)
Institutional Owners1
Institutional Shares32,819
Institutional Value$ 1,729,000 USD

Institutional Stock Ownership and Shareholders()

WSP Global Inc (OTC:WSPOF) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 32,819 shares. Largest shareholders include Gulf International Bank (UK) Ltd.
WSP Global Inc (OTC:WSPOF) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-07-05 13F-HR Gulf International Bank (UK) Ltd 32,819 1,729

Related Articles

ADAP: Adaptimmune Therapeutics Analysis and Research Report

2h - Asif

Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

Related News Stories

WSP Global's (WSPOF) CEO Alexandre L'Heureux on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Good afternoon, ladies and gentlemen. Welcome to the WSP's First Quarter of 2018 Results Conference Call. I would now like to turn the meeting over to Isabelle Adjahi, Senior Vice President Investor Relations and Communications. Please go ahead. Ms. Adjahi. (2-0)

WSP Global Inc 2018 Q1 - Results - Earnings Call Slides

2018-05-10 seekingalpha
The following slide deck was published by WSP Global Inc in conjunction with their 2018 Q1 earnings call. (2-0)

WSP Global Inc 2017 Q4 - Results - Earnings Call Slides

2018-03-16 seekingalpha
The following slide deck was published by WSP Global Inc in conjunction with their 2017 Q4 earnings call. (2-0)

WSP Global's (WSPOF) CEO Alexandre L'Heureux on Q4 2017 Results - Earnings Call Transcript

2018-03-15 seekingalpha
[Call Started Abruptly] Good organic growth in net revenues of 4.6%. This region delivered adjusted EBITDA and adjusted EBITDA margin before global corporate costs of $220.2 million and 13.3%, respectively. Once again, the highest among all of our reportable operating segments. The pipeline of opportunities for the Americas remain healthy and we are pleased to have been selected to provide services related to the development of the Giant Magellan Telescope, the first of the next generation of giant ground-based telescopes. (2-0)

CUSIP: 92938W202